Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1971 1
1973 1
1976 1
1980 1
1981 2
1983 1
1985 3
1986 4
1987 2
1988 2
1989 3
1990 3
1991 1
1992 4
1993 5
1994 3
1996 2
1999 2
2001 1
2002 2
2004 2
2005 1
2007 1
2012 6
2013 4
2014 3
2015 2
2016 4
2017 3
2018 1
2019 2
2020 1
2021 3
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

73 results

Results by year

Filters applied: . Clear all
Page 1
Orofacial Movement Disorders.
Clark GT, Ram S. Clark GT, et al. Oral Maxillofac Surg Clin North Am. 2016 Aug;28(3):397-407. doi: 10.1016/j.coms.2016.03.003. Oral Maxillofac Surg Clin North Am. 2016. PMID: 27475514 Review.
Orofacial movement disorders (OMDs) include dystonia, dyskinesia, drug-induced extrapyramidal reactions, and bruxism. The definition, epidemiology, pathophysiology, clinical features, and management are detailed. OMDs are often disabling and affect patients' overall qualit …
Orofacial movement disorders (OMDs) include dystonia, dyskinesia, drug-induced extrapyramidal reactions, and bruxism. The definition, epidem …
Orofacial dyskinesia. Clinical features, mechanisms and drug therapy.
Kobayashi RM. Kobayashi RM. West J Med. 1976 Oct;125(4):277-88. West J Med. 1976. PMID: 23611 Free PMC article. Review.
Several biochemical mechanisms have been proposed as causes, including hypersensitivity or partially deneverated brain dopamine receptors and low affinity of the offending drugs for brain muscarinic cholinergic receptors. Clinical therapy has been attempted primarily with …
Several biochemical mechanisms have been proposed as causes, including hypersensitivity or partially deneverated brain dopamine receptors an …
A review for the pharmacological effect of lycopene in central nervous system disorders.
Chen D, Huang C, Chen Z. Chen D, et al. Biomed Pharmacother. 2019 Mar;111:791-801. doi: 10.1016/j.biopha.2018.12.151. Epub 2019 Jan 4. Biomed Pharmacother. 2019. PMID: 30616078 Free article. Review.
In some special conditions such as ethanol addiction and haloperidol-induced orofacial dyskinesia, lycopene administration displays special therapeutic effects. ...
In some special conditions such as ethanol addiction and haloperidol-induced orofacial dyskinesia, lycopene administration dis …
Lisuride in parkinsonism.
Parkes JD, Schachter M, Marsden CD, Smith B, Wilson A. Parkes JD, et al. Ann Neurol. 1981 Jan;9(1):48-52. doi: 10.1002/ana.410090109. Ann Neurol. 1981. PMID: 7212665
In nine subjects with idiopathic, postencephalitic, or drug-induced parkinsonism, lisuride at a dosage of 0.05 to 0.15 mg intravenously caused an immediate improvement in tremor, rigidity, akinesia, and postural deformity, but also caused chorea and orofacial dyskinesia …
In nine subjects with idiopathic, postencephalitic, or drug-induced parkinsonism, lisuride at a dosage of 0.05 to 0.15 mg intravenously caus …
Naringin Ameliorates Haloperidol-Induced Neurotoxicity and Orofacial Dyskinesia in a Rat Model of Human Tardive Dyskinesia.
Wang MH, Yang CC, Tseng HC, Fang CH, Lin YW, Soung HS. Wang MH, et al. Neurotox Res. 2021 Jun;39(3):774-786. doi: 10.1007/s12640-021-00333-1. Epub 2021 Feb 1. Neurotox Res. 2021. PMID: 33523404
Animal models of haloperidol (HAL)-induced neurotoxicity and orofacial dyskinesia (OD) have long been used to study human tardive dyskinesia (TD). ...Our results first demonstrate the neuroprotective effects of NAR against HAL-induced OD, suggesting that NAR may hel …
Animal models of haloperidol (HAL)-induced neurotoxicity and orofacial dyskinesia (OD) have long been used to study human tard …
Adrafinil-induced orofacial dyskinesia.
Thobois S, Xie J, Mollion H, Benatru I, Broussolle E. Thobois S, et al. Mov Disord. 2004 Aug;19(8):965-6. doi: 10.1002/mds.20154. Mov Disord. 2004. PMID: 15300665
Effect of Biperiden Treatment in Acute Orofacial and Extremity Dyskinesia With Methylphenidate Therapy.
Arslan EA, Arslan E, Kilinç A, Göksu Ö. Arslan EA, et al. Pediatr Emerg Care. 2018 Nov;34(11):e217-e218. doi: 10.1097/PEC.0000000000001102. Pediatr Emerg Care. 2018. PMID: 28328695
OROS methylphenidate was discontinued, and the patient's symptoms resolved within 20 minutes after injection of biperiden by intravenous route (0.04 mg/kg). We wish to emphasize that acute orofacial dyskinesia and extremity dyskinesia can be observed during methylph …
OROS methylphenidate was discontinued, and the patient's symptoms resolved within 20 minutes after injection of biperiden by intravenous rou …
Orofacial dyskinesia after moxifloxacin treatment--a case with normal hepatorenal function and review of literature.
Mittal SO, Machado DG, Jabbari B. Mittal SO, et al. Clin Neuropharmacol. 2012 Nov-Dec;35(6):292-4. doi: 10.1097/WNF.0b013e31826ba0eb. Clin Neuropharmacol. 2012. PMID: 23151468 Review.
BACKGROUND: Orofacial dyskinesia is rarely reported with antibiotics. Among antibiotics, third-generation fluoroquinolones are known to cause movement disorders. We report the first patient who developed orofacial dyskinesia after taking a fourth-gener …
BACKGROUND: Orofacial dyskinesia is rarely reported with antibiotics. Among antibiotics, third-generation fluoroquinolones are …
Methylphenidate-induced acute orofacial and extremity dyskinesia.
Yilmaz AE, Donmez A, Orun E, Tas T, Isik B, Sonmez FM. Yilmaz AE, et al. J Child Neurol. 2013 Jun;28(6):781-3. doi: 10.1177/0883073812449905. Epub 2012 Jul 12. J Child Neurol. 2013. PMID: 22791547
In this article, the authors report a 7-year-old male patient who presented with orofacial and limb dyskinesia after his first dose of methylphenidate treatment for a diagnosis of attention-deficit/hyperactivity disorder; he was also receiving sodium valproate treatment for epile …
In this article, the authors report a 7-year-old male patient who presented with orofacial and limb dyskinesia after his first dose of methy …
73 results